Comprehensive Overview of GLP-1 RAs in Cardiometabolic Care
The not-so-sudden rise of weight loss ”wonder” drugs for T2D and obesity This World Obesity Day, March 4, 2024, weight loss drugs dominate discussions and raise new questions for clinicians. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have been used to treat type 2 diabetes (T2D) since the approval of Byetta (exenatide) in 2005. In the […]
GLP-1 Receptor Agonist Lixisenatide Approved by US FDA
The GLP-1 receptor agonist lixisenatide has received US FDA approval for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. Approval was based on 11 clinical trials that evaluated more than 11,000 patients, including a cardiovascular outcomes trial, ELIXA, that showed no increase in adverse cardiovascular events. Efficacy studies […]
GLP-1 Agonist Liraglutide Shown to Significantly Reduce the Risk of Major Adverse Cardiovascular Events in LEADER
Results of the cardiovascular outcomes LEADER trial have shown the GLP-1 agonist liraglutide to significantly reduce the risk of major adverse cardiovascular events. The trial, which began in 2010, included 9340 high-risk adults with type 2 diabetes who were randomized to either placebo or liraglutide along with standard treatment. The primary endpoint of LEADER was […]
Lixisenatide Proves Safety in ELIXA While Liraglutide Shows Greater HbA1c Reduction Compared with SGLT-2 Inhibitors
CV outcomes data from the ELIXA trial have been published in the New England Journal of Medicine for the as-yet FDA unapproved GLP-1 agonist lixisenatide, and have shown no increase or decrease in the rate of major cardiovascular events in patients with acute coronary syndrome. Read more here. Meanwhile, findings from a recent meta-analysis have […]
GLP-1 Agonist Liraglutide Significantly Decreases CV Risk and Mortality: Full Results From LEADER Presented
The GLP-1 agonist liraglutide has been shown to significantly decrease the risk of major cardiovascular events and death from any cause over a 3-year period: a 13% relative risk reduction, when compared with placebo as add-on therapy, according to results from the LEADER trial presented at the annual meeting of the American Diabetes Association (ADA). […]
